ElitePharmaceuticalsInc_OTC_ELTP_202310-K.pdf

1、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31,2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 COMMIS

2、SION FILE NUMBER:001-15697 ELITE PHARMACEUTICALS,INC.(Exact Name of Registrant as Specified in Its Charter)NEVADA 22-3542636(State or other jurisdiction ofincorporation or organization)(I.R.S.EmployerIdentification No.)165 LUDLOW AVENUENORTHVALE,NEW JERSEY 07647(Address of principal executive office

3、s)(Zip Code)(201)750-2646(Registrants telephone number,including area code)Securities registered pursuant to Section 12(g)of the Act:Title of each class Trading Symbol Name of each exchange on which registeredCommon Stock,par value$0.001 per share ELTP OTCQB Indicate by check mark if the registrant

4、is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d)of the SecuritiesExchange Act of 1934.Yes No Indicate by check mark whether the registrant(1)has filed a

5、ll reports required to be filed by Section 13 or 15(d)of the SecuritiesExchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was required to file suchreports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check

6、 mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T(232.405 of this chapter)during the preceding 12 months(or for such shorter period thatthe registrant was required to submit such files).Yes No Indicate